LENZ Therapeutics (LENZ) Capital Expenditures (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Capital Expenditures data on file, last reported at -$1000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 100.91% year-over-year to -$1000.0 in Q1 2026; TTM through Mar 2026 was -$111000.0, a 119.2% decrease from a year earlier, with the FY2024 full-year figure at $468000.0, up 4780.0% from the prior year.
• Capital Expenditures for Q1 2026 stood at -$1000.0, up from -$789000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for LENZ reached as high as $3.3 million in Q1 2022 and fell as low as -$789000.0 in Q4 2025.
• Historically, Capital Expenditures has averaged $542384.6 across 5 years, with a median of $149000.0 in 2024.
• Across the five-year window, Capital Expenditures jumped 809.17% in 2022 and tumbled 629.53% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $1.0 million in 2022, then sank by 101.57% to -$16000.0 in 2023, then jumped by 1031.25% to $149000.0 in 2024, then tumbled by 629.53% to -$789000.0 in 2025, then soared by 99.87% to -$1000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$1000.0 in Q1 2026, -$789000.0 in Q4 2025, and $585000.0 in Q3 2025.